Skip to content

NIH ALS Expanded Access U01 Eligibility

Updated 6 official sources

Quick Answer: NIH ALS expanded access U01 eligibility is narrow. RFA-NS-26-001 shows $40,000,000 in program funding and 4 expected awards, but applicants must fit the clinical-trial-site and FDA-designated IND sponsor structure for investigational ALS drugs or biological products.

Full answer and how we checked it

Most ALS researchers and patient groups will not fit this route. The 2026 decision turns on 7 checks.

Who this is for: Clinical trial sites, ALS research centers, university sponsored research offices, and small-business partners deciding whether the expanded-access U01 route is real before organizing a proposal.

Data note: This guide uses the Simpler.Grants.gov listing and full announcement for RFA-NS-26-001, NIH U01 and clinical-trial policy pages, FDA expanded-access guidance, the live ALS expanded-access U01 program page, and Grantsights award-data signals checked on October 10, 2026.

In this guide

Quick Facts

Agency
HHS
Last deadline
Nov 10, 2026 (passed)
Status
Closed

Assistance Listing 93.853: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.853, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
7,925
Avg Award (whole listing)
$2,429,698
Median Award (whole listing)
$1,670,376
Total Funding (FY2024, whole listing)
$1.8B
YoY Funding Trend
+0.3%

Data last verified: May 18, 2026

This ALS opportunity is not a general research grant. According to Simpler.Grants.gov, the purpose is to support scientific research using data from expanded access for investigational drugs or biological products under section 561 of the Federal Food, Drug, and Cosmetic Act. The listing targets intermediate-size populations of people living with ALS who are not eligible for ongoing ALS clinical trials.

Use this guide with the live ALS expanded-access U01 program page, plus broader NIH route tools like NIH R01, R21, R03, and K awards, NIH grants complete guide, and how grant reviewers score applications. Teams can lose weeks on opportunities like this by reading the disease area and funding amount before the site and sponsor conditions.

Source Check

Checked October 2026.

5 official-source checks should happen before any site treats RFA-NS-26-001 as a lead application. The full announcement states that eligible applicants must be clinical trial sites participating in a phase 2/3 or phase 3 ALS efficacy clinical trial supported by a U.S.-based small business concern that is the FDA-designated IND sponsor of the drug or biological product. The public listing shows U01 clinical trial required status, $40,000,000 in program funding, 4 expected awards, no cost sharing, and a November 10, 2026 close date.

The route is also narrower than general expanded access interest. FDA explains expanded access as a path for patients with serious or life-threatening disease to receive investigational medical products outside a clinical trial when criteria are met. This NOFO then narrows that broader concept to ALS sites tied to the required trial and small-business sponsor structure.

Source checkWhat to verify before writing
Site roleApplicant is a participating clinical trial site, not only an ALS service provider
Trial phaseRelated ALS efficacy trial is phase 2/3 or phase 3
Sponsor roleU.S.-based small business is the FDA-designated IND sponsor
Patient groupExpanded-access population is not eligible for ongoing ALS trials
RestrictionsForeign organizations, foreign components, and non-U.S. components are not allowed

If any one of those facts fails, the team should compare R01, clinical-trial NOFO, registry, natural-history, foundation, or patient-service routes before spending proposal time.

NIH ALS Expanded Access U01 Eligibility: 4 Stop Checks

4 expected awards make the stop checks even more important before any budget or partner meeting. According to Simpler.Grants.gov, eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial supported by a small business concern that is the FDA-designated sponsor of the drug or biological product under an IND.

Stop checkPass signalRed flag
Trial-site roleApplicant is a qualifying clinical trial siteApplicant is only an advocacy group or service provider
Trial phaseRelated ALS trial is phase 2/3 or phase 3Earlier-phase or unrelated study
Sponsor statusSmall business is FDA-designated IND sponsorSponsor role is unclear
Patient populationExpanded access serves ALS patients not eligible for ongoing trialsGeneral ALS care or registry work

This is a narrow site-and-sponsor opportunity. The common mistake is seeing "ALS" and "expanded access" and assuming broad nonprofit eligibility. The listing's additional eligibility text is much tighter than that.

Funding, Timing, and Clinical-Trial Status

4 expected awards and $40,000,000 in program funding create a large-looking opportunity, but the route is constrained. The listing shows a November 10, 2026 closing date, RFA-NS-26-001 as the funding opportunity number, and cooperative agreement as the funding instrument. According to the full announcement (opens in a new tab), the RFA had two receipt dates: June 8, 2026, which has passed, and November 10, 2026, which is the last one before the notice expires on November 11, 2026. NINDS intends to commit up to $40,000,000 per fiscal year for 4 new awards per year, the maximum project period is 4 years, and the RFA reissues RFA-NS-25-024.

Listing signalPractical meaning
$40,000,000 program fundingLarge enough to support serious site work
4 expected awardsCompetition will be narrow and selective
U01 cooperative agreementNIH involvement is expected
Clinical trial requiredTrial operations and data rules matter
No cost sharingMatching funds are not listed as required

According to USAspending.gov (opens in a new tab) data, NINDS assistance listing 93.853 had about $1.83B in FY2024 obligations across 7,925 awards active that year. That broad family data supports market context, while the live listing controls this specific opportunity.

According to NIH and Simpler.Grants.gov, the live RFA-NS-26-001 listing shows $40,000,000 in program funding and 4 expected awards, which is why the site and sponsor screen has to happen before a full proposal build.

U01 vs R01, Clinical Trial, Registry, and Foundation Routes

$40,000,000 in listed program funding does not remove the need to compare 5 alternative routes before committing. A standard R01 may fit mechanistic ALS research. A clinical-trial NOFO may fit treatment testing. A registry or natural-history study may fit if no expanded access product is involved. Foundation ALS funding may fit advocacy or patient-support work.

RouteBetter first read when...Why
ALS expanded-access U01Site and IND sponsor rules are metListing requirements match
R01Research question is investigator-ledNo expanded access structure needed
Clinical trial NOFOIntervention testing is the main activityTrial route is more direct
Registry or natural-history routeData collection is not tied to expanded accessPatient-data purpose differs
ALS foundation grantPatient service, pilot, or advocacy scopeFederal clinical structure may not fit

If the team is not a qualifying clinical trial site, don't force the U01. Use NIH grant types comparison for mechanism choice and the ALS expanded-access U01 program page for current status.

What NIH Doesn't Tell You

$40,000,000 can make this look like a major opening, but the real filter is structural. NIH and Simpler.Grants.gov give the eligibility language. They do not tell a site whether the sponsor relationship, trial status, patient population, and data plan are strong enough.

First, the official listing cannot fix a weak sponsor relationship. If the small business sponsor is not ready to support the data, product, IND, and site operations, the site may be eligible in theory but weak in practice.

Second, the official listing does not solve patient-population documentation. Expanded access is meant for people with ALS who are not eligible for ongoing trials. That must be documented carefully, not treated as a broad access phrase.

Third, the official listing does not compare the U01 against ordinary ALS research funding. A lab studying disease mechanism, biomarkers, or care delivery may need R01, R21, or foundation support instead.

Fourth, the official listing does not pair the opportunity with Grantsights family-level funding data. Grantsights data shows a large NINDS-connected family, but this U01 is still a 4-award, clinical-trial-required competition.

The honest warning: if the site cannot explain the trial-site role, the IND sponsor role, and the expanded-access population in the first 2 pages, the application is likely not ready.

5 Real-World ALS U01 Scenarios

7,925 connected family awards active in FY2024 provide context, but 5 scenarios show how fast the route can change. For example, an ALS center participating in a phase 3 trial with a small-business IND sponsor may be a possible fit. A nonprofit that funds patient transport, caregiver support, and advocacy should probably look elsewhere.

ScenarioBetter routeWhy
Trial site tied to qualifying small-business IND sponsorU01Eligibility structure fits
Patient advocacy nonprofit with no trial-site roleFoundation or subaward pathApplicant role is weak
Basic ALS mechanism labR01 or R21No expanded access structure
Registry team collecting observational dataRegistry or data NOFODifferent evidence purpose
Hospital wants to join but lacks sponsor agreementWait or partnerSponsor link is missing

A trial site might have the infrastructure, ALS patient volume, and sponsor agreement needed to assemble the U01. A university team might have strong ALS science but no qualifying trial-site role. That second team should not spend a full cycle forcing eligibility.

Draft Checks to Run First

4 expected awards and a November 10, 2026 closing date mean 7 checks decide whether the opportunity deserves proposal time.

  1. Confirm the applicant is a clinical trial site.
  2. Confirm the related ALS trial is phase 2/3 or phase 3.
  3. Confirm the small business is the FDA-designated IND sponsor.
  4. Confirm the patient group is not eligible for ongoing clinical trials.
  5. Confirm foreign organization and foreign component restrictions.
  6. Confirm clinical-trial-required application pieces are ready.
  7. Compare the opportunity against R01, trial-specific NOFOs, registry routes, and foundation ALS support.

According to Grants.gov, the opportunity was posted and last updated May 4, 2026. According to Grantsights data, the NINDS-connected family shows about $1.83B in FY2024 obligations, but the strongest applicant screen remains the site, sponsor, and expanded-access fact pattern.

8 ALS Expanded-Access Questions Before Writing

8 questions should be answered before a site treats this as a lead application. According to NIH clinical-trial policy, trial-required applications carry extra protocol, human-subject, safety, and data expectations. According to Simpler.Grants.gov, this listing is tied to expanded access for investigational ALS drugs or biological products, so the applicant cannot treat it like a normal research grant.

The first question is whether the applicant is truly a qualifying site. A strong ALS care center is not automatically a qualifying site. The listing points to clinical trial sites participating in the required phase 2/3 or phase 3 trial structure.

The second question is whether the sponsor relationship is signed and specific. According to NIH, a U01 is a cooperative agreement, so NIH involvement is expected. The site also needs a clear small-business sponsor relationship, because the listing ties eligibility to a small business that is the FDA-designated IND sponsor.

The third question is whether the expanded-access population is documented. Patients living with ALS who are not eligible for ongoing clinical trials are the named population. If the site can't define that population, referral path, and documentation process, the application will be soft.

The fourth question is whether the data plan serves research rather than only access. Expanded access can help patients, but this NOFO is also about scientific research using the data. The application should explain what will be collected, how quality will be maintained, and how missing data will be handled.

The fifth question is whether the site can handle a cooperative agreement. Reporting cadence, program contact, human-subject oversight, and protocol changes can all move faster than in a standard grant. The organization should have staff who can manage that load.

The sixth question is whether the foreign restriction affects partners. The listing says non-U.S. entities, non-U.S. components, and foreign components are not eligible. International clinical collaborators may be scientifically valuable, but they can create a compliance problem for this specific route.

The seventh question is whether a different ALS route is stronger. An R01 can fund mechanism work. A trial NOFO can fund intervention testing. A foundation award may fit care access, equipment, or patient-service work. Don't bend the U01 around work it wasn't built to fund.

The eighth question is whether the site can explain the whole case in 90 seconds: site role, phase 2/3 or phase 3 trial, small-business IND sponsor, expanded-access population, U01 capacity, and data plan. If that oral answer isn't crisp, the written application will probably sprawl.

A center with ALS trial infrastructure, a qualifying sponsor relationship, and documented demand from patients who can't enter ongoing trials is a possible fit. A research lab with strong ALS biomarker science but no trial-site role isn't. That project should look elsewhere first.

7 ALS U01 Route Checks Updated October 10, 2026

7 checks now separate official source facts from project-specific scoring. First, verify the RFA-NS-26-001 listing and full announcement before using a copied deadline. Second, confirm the applicant is a clinical trial site tied to the required ALS efficacy trial. Third, confirm the phase 2/3 or phase 3 status. Fourth, document the U.S.-based small-business FDA-designated IND sponsor.

Fifth, define the expanded-access patient group and why those people are not eligible for ongoing trials. Sixth, remove foreign organization and foreign component assumptions from the plan. Seventh, compare the U01 against R01, trial, registry, natural-history, foundation, and patient-service routes before treating the $40,000,000 figure as proof of fit.

Checked on October 10, 2026 against the Simpler Grants listing (opens in a new tab), NIH U01 activity code (opens in a new tab), NIH clinical trial policy (opens in a new tab), FDA expanded access (opens in a new tab), and USASpending.gov (opens in a new tab).

CheckPublic answer
EligibilityConfirm the applicant, institution, and route rules for NIH ALS expanded access U01 eligibility.
Source statusVerify the official listing, notices, due date, and expiration status.
BudgetCheck award size, cost limits, match, or budget logic when the source provides it.
EvidenceName the data, preliminary work, partner role, or implementation proof needed.
Bad fitStop if the project belongs in a nearby NIH or federal route.
Review criteriaTie the first page to significance, approach, team, environment, and source-specific criteria.
Next actionDecide whether to draft, ask a program contact, redirect, or move to a nearby route.

Final public checklist

  • Confirm whether U01 is the right route or whether a nearby program fits better.
  • Check budget, partner, match, or data-readiness constraints.

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 7,925 Assistance Listing records | Avg: $2.4M

REAL DATA
1

University of California, Los Angeles

CA

$996.1M
2

President and Fellows of Harvard College

MA

$88.3M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Frequently Asked Questions

Who is eligible for the ALS expanded-access U01?

Eligible applicants must be clinical trial sites participating in a phase 2/3 or phase 3 ALS efficacy trial supported by a small business that is the FDA-designated IND sponsor of the drug or biological product.

How much funding is available?

The Simpler.Grants.gov listing shows $40,000,000 in program funding and 4 expected awards for RFA-NS-26-001.

Does this ALS U01 require a clinical trial?

Yes. The listing identifies this opportunity as U01 clinical trial required.

Are foreign organizations eligible?

No. The listing states that non-U.S. entities, non-U.S. components, and foreign components are not eligible.

Who should skip this opportunity?

Skip it if the applicant is not an eligible clinical trial site tied to the required ALS phase 2/3 or phase 3 efficacy trial and IND sponsor structure.

Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.